Zoar lists on NYSE American via Impact Biomedical merger backed by DSS
What's the deal? DSS, Inc. said Impact BiomedicalDealroom has a profile for this one. Try Dealroom → — the company in which it held a majority stake — has completed its business combination with Zoar Limited and Zoar Labs Limited. Impact Biomedical becomes a wholly owned subsidiary renamed Zoar USA Inc., with its shares converting one-for-one into Zoar Limited ordinary shares.
Why now? The deal closes a process that began in June 2025. Impact Biomedical stockholders approved the combination at a November 13, 2026 special meeting, and Zoar Limited shares are expected to begin trading on the NYSE American under ticker "ZOAR" on November 18, 2026.
What's the endgame? The transaction gives Zoar — a global pharmaceutical company focused on active pharmaceutical ingredients, intermediates, and contract manufacturing — a public listing. For DSS, chief executive officer Jason Grady called it "a meaningful milestone," saying the deal "introduces an established international pharmaceutical operating business to the public markets."
The numbers: Zoar Labs reported about $651.7 million in revenue and $77.7 million in net income for the fiscal year ended March 31, 2026 — up roughly 17.1% and 23.9% year over year. DSS noted these figures relate to Zoar Labs and do not represent its own consolidated results.
What could go wrong? The ownership is lopsided. Former Impact shareholders collectively hold about 4.8% of roughly 180 million shares outstanding, while Zoar Labs' owner holds about 93.3%. The announcement does not establish how much value or proceeds DSS ultimately receives.
The signal: This is chiefly a public listing and ownership reshaping around Zoar Labs, not evidence that Impact's own business has become a large contributor. DSS keeps its "DSS" ticker and says it will detail the deal's effect on its holdings through future SEC filings.
Read more: wallstreet-online.de
Image credit: Generated with Gemini